摘要
Abstract
Objective To observe clinical effect of recombinant human type Ⅱ tumor necrosis factor receptor-antibody fusion protein and immunosuppressive agents in treatment of patients with ankylosing spondylitis ( AS) . Meth-ods Clinical data of 123 AS patients during January 2014 and February 2015 was retrospectively analyzed, and the pa-tients were divided into group A, B and C ( n=41 for each group) according to therapic method. Group A received sub-cutaneous injection of recombinant human typeⅡtumor necrosis factor receptor-antibody fusion protein, and group B re-ceived subcutaneous injection of Etanercept, and group C was treated with Sulfasalazine orally. In 3 groups, clinical cur-ative effects and incidence rates of adverse reactions were observed, and times of symptom improvement were analyzed, and then peripheral joint pain score, score of swelling degree, erythrocyte sedimentation rate ( ESR) and improvement conditions of inflammatory factor indexes before and after treatment were also recorded. Results Total effective rates in group A and B were significantly higher than that in group C. After 12 weeks of treatment, scores of pain and peripheral joint swelling degree decreased, and levels of ESR, c-reactive protein ( CRP) , tumor necrosis factor-α( TNF-α) , inter-leukin-33 (IL-33) and IL-17 were lower than those before treatment in 3 groups, and the above values in group A and B were lower than those in group C (P<0. 05);relief times of symptoms such as lumbar and back pains, peripheral joint pain, peripheral joint swelling, morning stiffness were shorter, and incidence rates of adverse reactions in group A and B were lower than those in group C (P<0. 05). Conclusion Recombinant human typeⅡtumor necrosis factor receptor-antibody fusion protein and Etanercept has better effect with milder adverse reactions in treatment of AS patients than that by Sulfasalazine. It is recommended that patient's condition should be taken into consideration in choosing which is the best medication regimen.关键词
受体,肿瘤坏死因子,Ⅱ型/免疫抑制剂/脊柱炎,强直性Key words
Receptors, tumor necrosis factor, type Ⅱ/Immunosuppressive agents/Spondylitis, ankylosing分类
医药卫生
